CLDI (Calidi Bio) קצב צמיחת רווח למניה בשנה הנוכחית

Calidi Biotherapeutics R&D efficiency relies on precision cryogenic stem cell logistics. The YoY earnings per share growth rate on this GURU.Markets chart reflects a trend where the value 0.00 describes the current level. Humanitarian medical protection protocols guarantee business stability, while management focuses on creating unique viral cancer therapy methods.

The resilience of Calidi Biotherapeutics (CLDI) is determined by its effectiveness in attracting investment for the development of oncolytic therapies. By analyzing annual EPS fluctuations, an investor can see the impact of clinical trial costs on net income. This metric calculates the percentage change in earnings per share relative to the previous year, allowing for an assessment of capital growth or contraction rates to determine the asset's fair value.